Merck & Co., Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Merck & Co., Inc. (MRK) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $1.70 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-02-24
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-12-31 was $230.00M, a 93.19% decline year-over-year.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2017-09-30 was $245.00M, a 4800.00% increase year-over-year.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-12-31 was $3.38B, a 337400.00% increase year-over-year.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2016-09-30 was $5.00M, a 400.00% increase year-over-year.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $1.70B.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $172.00M, a 13.16% increase from fiscal 2018.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $152.00M, a 68.53% decline from fiscal 2017.
- Merck & Co., Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $483.00M, a 86.58% decline from fiscal 2016.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $1.70B 10-K · filed 2023-02-24 | ||||
| 2019-12-31 | $172.00M 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | $152.00M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $230.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $475.00M derived: sum of 2 quarters · filed 2020-02-26 | $483.00M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $245.00M 10-Q · filed 2018-11-06 | $253.00M 10-Q · filed 2018-11-06 | |||
| 2016-12-31 | $3.38B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.38B derived: sum of 2 quarters · filed 2019-02-27 | $3.58B derived: sum of 3 quarters · filed 2019-02-27 | $3.60B 10-K · filed 2019-02-27 | |
| 2016-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $200.00M derived: sum of 2 quarters · filed 2017-11-07 | $225.00M 10-Q · filed 2017-11-07 | $226.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $195.00M 10-Q · filed 2017-08-08 | $220.00M 10-Q · filed 2017-08-08 | $221.00M derived: sum of 3 quarters · filed 2018-02-27 | $222.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $25.00M 10-Q · filed 2017-05-09 | $26.00M derived: sum of 2 quarters · filed 2018-02-27 | $27.00M derived: sum of 3 quarters · filed 2018-02-27 | $86.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.00M derived: sum of 2 quarters · filed 2018-02-27 | $61.00M derived: sum of 3 quarters · filed 2018-02-27 | $63.00M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $60.00M derived: sum of 2 quarters · filed 2016-11-07 | $62.00M 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | $59.00M 10-Q · filed 2016-08-08 | $61.00M 10-Q · filed 2016-08-08 | |||
| 2014-12-31 | $49.00M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $36.00M 10-Q · filed 2014-11-10 | ||||
| 2013-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $15.00M derived: sum of 2 quarters · filed 2016-02-26 | $249.00M derived: sum of 3 quarters · filed 2016-02-26 | $279.00M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $234.00M derived: sum of 2 quarters · filed 2014-11-10 | $264.00M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $234.00M 10-Q · filed 2014-08-07 | $264.00M 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $64.00M derived: sum of 2 quarters · filed 2015-02-27 | $191.00M derived: sum of 3 quarters · filed 2015-02-27 | $200.00M 10-K · filed 2015-02-27 | |
| 2012-09-30 | $40.00M 10-Q · filed 2012-11-09 | $167.00M derived: sum of 2 quarters · filed 2012-11-09 | $176.00M 10-Q · filed 2012-11-09 | $420.00M derived: sum of 4 quarters · filed 2014-02-27 | |
| 2012-06-30 | $127.00M 10-Q · filed 2012-08-07 | $136.00M 10-Q · filed 2012-08-07 | $380.00M derived: sum of 3 quarters · filed 2014-02-27 | $402.00M derived: sum of 4 quarters · filed 2014-02-27 | |
| 2012-03-31 | $9.00M 10-Q · filed 2012-05-08 | $253.00M derived: sum of 2 quarters · filed 2014-02-27 | $275.00M derived: sum of 3 quarters · filed 2014-02-27 | $294.00M derived: sum of 4 quarters · filed 2014-02-27 | |
| 2011-12-31 | $244.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $266.00M derived: sum of 2 quarters · filed 2014-02-27 | $285.00M derived: sum of 3 quarters · filed 2014-02-27 | $587.00M 10-K · filed 2014-02-27 | |
| 2011-09-30 | $22.00M 10-Q · filed 2012-11-09 | $41.00M derived: sum of 2 quarters · filed 2012-11-09 | $343.00M 10-Q · filed 2012-11-09 | $2.53B derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-06-30 | $19.00M 10-Q · filed 2012-08-07 | $321.00M 10-Q · filed 2012-08-07 | $2.50B derived: sum of 3 quarters · filed 2013-02-28 | $2.69B derived: sum of 4 quarters · filed 2013-02-28 | |
| 2011-03-31 | $302.00M 10-Q · filed 2012-05-08 | $2.49B derived: sum of 2 quarters · filed 2013-02-28 | $2.67B derived: sum of 3 quarters · filed 2013-02-28 | $2.67B derived: sum of 4 quarters · filed 2013-02-28 | |
| 2010-12-31 | $2.18B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $2.37B derived: sum of 2 quarters · filed 2013-02-28 | $2.37B derived: sum of 3 quarters · filed 2013-02-28 | $2.40B 10-K · filed 2013-02-28 | $2.44B 10-K · filed 2011-02-28 |
| 2010-09-30 | $189.00M 10-Q · filed 2011-11-08 | $189.00M derived: sum of 2 quarters · filed 2011-11-08 | $216.00M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | $27.00M 10-Q · filed 2011-08-08 | |||
| 2010-03-31 | $27.00M 10-Q · filed 2011-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |